Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.
Amit M. Oza
Research Funding - AstraZeneca
David Cibula
No relevant relationships to disclose
Ana Oaknin
No relevant relationships to disclose
Christopher John Poole
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Ron H.J. Mathijssen
No relevant relationships to disclose
Gabe S. Sonke
No relevant relationships to disclose
Nicoletta Colombo
No relevant relationships to disclose
Jirí Špacek
No relevant relationships to disclose
Peter Vuylsteke
Honoraria - AstraZeneca
Expert Testimony - AstraZeneca
Other Remuneration - AstraZeneca
Hal W. Hirte
No relevant relationships to disclose
Sven Mahner
No relevant relationships to disclose
Marie Plante
No relevant relationships to disclose
Barbara Schmalfeldt
No relevant relationships to disclose
Helen Mackay
No relevant relationships to disclose
Jacqui Rowbottom
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ilian Tchakov
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Michael Friedlander
Consultant or Advisory Role - AstraZeneca